Transient costimulatory blockade overcomes immune barriers to durable and redosable liver-directed gene therapy
This study demonstrates that combining liver-directed lentiviral gene therapy with transient costimulatory blockade overcomes adaptive immune barriers to achieve durable therapeutic factor VIII expression, immune tolerance, and the ability to safely redose the therapy in a mouse model of hemophilia A.